UK-based STORM Therapeutics Ltd’s corporate strategy has received a significant boost with the publication in Nature showing the biotech’s first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy for treating acute myeloid leukemia as well as solid tumours, clearing the way for human clinical trials in early 2022.
Spun out of Cambridge University in 2015, STORM aims to tackle disease through modulating RNA-modifying enzymes
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?